Evidence map›Paper›PMID 30532215›Full record

Trial reportPloS one2018

Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET/CT for prediction of tumor recurrence in breast cancer.

Ji-In Bang, Hai-Jeon Yoon, Bom Sahn Kim

Abstract readClinical Trial
In one paragraph

Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Baseline fdg pet/ct-derived tumor burden and host metabolic activity predict complete metabolic response to neoadjuvant chemotherapy in ınvasive ductal breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Review
  3. Article
  4. BaselineLa Radiologia medica · 2025
    Article
  5. Prognostic significance of diffuse increased fluorine-18-fluorodeoxyglucose (Quantitative imaging in medicine and surgery · 2024
    Article
  6. Article
  7. Evaluating the correlation between pretreatmentPathology oncology research : POR · 2024
    Article
  8. Advances in PET/CT Imaging for Breast Cancer.Journal of clinical medicine · 2023
    Review
  9. Article
  10. Article
  11. Spleen glucose metabolism on [European journal of nuclear medicine and molecular imaging · 2021
    Article
  12. [EJNMMI research · 2020
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ji-In BangDepartment of Nuclear Medicine, Ewha Womans University School of Medicine, Seoul, South Korea.
Hai-Jeon YoonDepartment of Nuclear Medicine, Ewha Womans University School of Medicine, Seoul, South Korea.
Bom Sahn KimDepartment of Nuclear Medicine, Ewha Womans University School of Medicine, Seoul, South Korea.ORCID 0000-0003-2520-7182

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to investigate the metabolism of the spleen, bone marrow (BM), and liver from preoperative F-18 FDG PET/CT scans for the prediction of recurrence in breast cancer.

methodsWe retrospectively included 153 patients diagnosed with invasive ductal carcinoma (IDC) of the breast who underwent preoperative F-18 FDG PET/CT scan and a curative operation. The mean standardized uptake value (SUVmean) of the spleen, liver, and BM and maximum SUV (SUVmax) of primary tumors were measured. The relationships between spleen, BM, and liver metabolism and clinicopathologic parameters were evaluated, and possible prognostic parameters predicting recurrence were assessed using disease-free survival (DFS).

resultsSpleen SUVmean was significantly correlated with primary tumor SUVmax, pathologic T (pT) stage, and histologic grade of primary tumor. BM SUVmean also showed a positive correlation with primary tumor SUVmax. Spleen SUVmean were significantly associated with recurrence from binary logistic regression analysis (P = 0.004). Spleen, BM, liver, and primary tumor SUVs were all significant prognostic factors for DFS in univariate Cox regression analysis (all P<0.024). Among all PET parameters analyzed, spleen SUVmean ≥ 2.21 (P = 0.032) was in the multivariable analysis the powerful poor prognostic factor predicting DFS that was independent of other clinicopathological features like T stage (pT >2; P = 0.009) and estrogen receptor (ER) status (ER negativity; P = 0.001).

conclusionSplenic metabolism together with pT stage and ER status was an independent prognostic factor for predicting recurrence in breast cancer. Metabolic activity of reticuloendothelial system such as spleen, liver or BM on preoperative F-18 FDG PET/CT can be a meritorious imaging factor for discriminating patients with IDC that require adjunctive therapy to prevent recurrence.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastMononuclear Phagocyte SystemNeoplasm Recurrence, LocalPositron-Emission TomographyTomography, X-Ray ComputedAdultAgedBone MarrowFemaleGlucose-6-PhosphateHumansLiverMiddle AgedNeoplasm MetastasisPredictive Value of Tests2-fluoro-2-deoxyglucose-6-phosphateGlucose-6-Phosphate

Identifiers

PMID30532215
PMCPMC6286142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.